MLYS - Mineralys Therapeutics Inc Quarterly EPS earnings growth

Mineralys Therapeutics - graphic logo of issuer MLYS

Mineralys Therapeutics (MLYS) operates under strict FDA oversight and high R&D expenditures. The GURU.Markets platform displays the quarterly EPS growth trend, where the figure reached -23.10. The target segment consists of hypertension patients and purchasing clinics. The company is currently focusing on completing the final stage of trials for its lead molecule to facilitate a prompt commercial launch.

Mineralys (MLYS) Year-over-year earnings per share growth for the last twelve months: for the period 04/28/2023 - 11/17/2026

Summary analytical data breakdowns for Mineralys Therapeutics, Inc. (MLYS)

- market value and analyst target forecast:
Summary company analytics:Mineralys Therapeutics, Inc., MLYS
Manufactured product of mineralystx.com

This indicator measures the rate of change in net income per share between the current and previous quarters. By analyzing quarterly growth in net income per share, an investor assesses the efficiency of income generation relative to the volume of issuance. The metric is extremely sensitive to one-time write-offs and operating expenses. For Mineralys Therapeutics (MLYS), this figure reflects high R&D costs. Negative dynamics confirm the depletion of reserves in the absence of stable sales.

Competitor analysis for Mineralys Therapeutics

Regeneron Pharmaceuticals (REGN) - Year-over-year earnings per share growth for the last twelve months|IRTC: Year-over-year earnings per share growth rate for the last twelve months|LNTH (Lantheus Holdings) - Quarterly EPS earnings growth|HeartFlow, Inc. - Year-over-year net earnings per share trend for the last twelve months|Year-over-year net earnings per share growth for the last 12 months KMTS (Kestra Medical)|ESPR - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth AMRN (Amarin Pharma)|Year-over-year earnings per share growth rate for the last twelve months AVR (Anteris Technologies Ltd)|Tenaya Therapeutics, Inc. - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months CVRx, Inc. CVRX|MIST (Milestone Pharmaceuticals Inc.) - Year-over-year net earnings per share growth for the last 12 months|Cardiol Therapeutics Inc - Year-over-year earnings per one share growth for the last 12 months|BEAT (HeartBeam Corporation) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Tenax Therapeutics Inc|Quarterly EPS earnings growth ADGM|BioCardia, Inc. - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth VTAK (Catheter Precision Inc)|ABIO - Year-over-year net earnings per share growth for the last 12 months|Acasti Pharma - Quarterly EPS earnings growth|AVTE - Quarterly EPS earnings growth|VERV (vervetx.com) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share trend for the last twelve months WINT (Windtree Therapeutics Inc.)